AR011521A1 - Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende - Google Patents

Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende

Info

Publication number
AR011521A1
AR011521A1 ARP980100097A ARP980100097A AR011521A1 AR 011521 A1 AR011521 A1 AR 011521A1 AR P980100097 A ARP980100097 A AR P980100097A AR P980100097 A ARP980100097 A AR P980100097A AR 011521 A1 AR011521 A1 AR 011521A1
Authority
AR
Argentina
Prior art keywords
formula
compound
derivative
methylamide
pharmaceutical composition
Prior art date
Application number
ARP980100097A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR011521A1 publication Critical patent/AR011521A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/22Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP980100097A 1997-01-14 1998-01-09 Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende AR011521A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9700597.9A GB9700597D0 (en) 1997-01-14 1997-01-14 Organic compounds

Publications (1)

Publication Number Publication Date
AR011521A1 true AR011521A1 (es) 2000-08-30

Family

ID=10805904

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100097A AR011521A1 (es) 1997-01-14 1998-01-09 Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende

Country Status (14)

Country Link
US (1) US6107293A (enExample)
EP (1) EP0964867B1 (enExample)
JP (2) JP4306804B2 (enExample)
AR (1) AR011521A1 (enExample)
AT (1) ATE290546T1 (enExample)
AU (1) AU5764298A (enExample)
CA (1) CA2278057C (enExample)
CO (1) CO4950614A1 (enExample)
DE (1) DE69732715T2 (enExample)
ES (1) ES2239368T3 (enExample)
GB (1) GB9700597D0 (enExample)
PT (1) PT964867E (enExample)
WO (1) WO1998031704A2 (enExample)
ZA (1) ZA98256B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
GB9815696D0 (en) * 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
CA2362290A1 (en) 1999-02-18 2000-08-24 Kaken Pharmaceutical Co., Ltd. Novel amide derivatives as growth hormone secretagogues
AU2000249828A1 (en) * 2000-05-03 2001-11-12 Taisho Pharmaceutical Co. Ltd. Stat4 and stat6 binding dipeptide derivatives
US6884782B2 (en) 2000-11-08 2005-04-26 Amgen Inc. STAT modulators
US20070219214A1 (en) * 2006-02-01 2007-09-20 Solvay Pharmaceuticals Gmbh Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation
CN101600724B (zh) 2006-10-16 2013-03-13 狮王株式会社 Nk1受体拮抗剂组合物
EP2729147B1 (en) 2011-07-04 2017-09-06 IRBM - Science Park S.p.A. Nk-1 receptor antagonists for treating corneal neovascularisation
WO2019162519A1 (en) 2018-02-26 2019-08-29 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210669A (en) * 1983-12-27 1988-05-30 Syntex Inc Benzoxazin-4-one derivatives and pharmaceutical compositions
GB8929070D0 (en) * 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
FR2719312B1 (fr) * 1994-04-28 1996-06-14 Adir Nouveau pseudopeptides dérivés de neurokinines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
DE69732715T2 (de) 2006-04-13
CA2278057C (en) 2004-05-04
ES2239368T3 (es) 2005-09-16
EP0964867A2 (en) 1999-12-22
JP4306804B2 (ja) 2009-08-05
ATE290546T1 (de) 2005-03-15
ZA98256B (en) 1998-07-14
WO1998031704A3 (en) 1998-09-11
AU5764298A (en) 1998-08-07
GB9700597D0 (en) 1997-03-05
EP0964867B1 (en) 2005-03-09
DE69732715D1 (de) 2005-04-14
JP2000516257A (ja) 2000-12-05
US6107293A (en) 2000-08-22
JP3817256B2 (ja) 2006-09-06
JP2006089499A (ja) 2006-04-06
WO1998031704A2 (en) 1998-07-23
CA2278057A1 (en) 1998-07-23
CO4950614A1 (es) 2000-09-01
PT964867E (pt) 2005-07-29

Similar Documents

Publication Publication Date Title
ES8506677A1 (es) Un procedimiento para la preparacion de nuevos derivados de 8-cloro71,5-benzotiazepina.
PT99317A (pt) Processo para a preparacao de novos compostos peptidicos e de composicoes farmaceuticas que os contem
AR017021A1 (es) Acido 2-hidroxiacetico
AR031828A2 (es) Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia
ITMI922006A1 (it) Esteri nitrici di derivati dell'acido 2-(2, 6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
AR029150A1 (es) Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende.
ES2043781T3 (es) Un procedimiento para la preparacion de nuevos derivados de 2beta-morfolino-androstano.
BR0109109A (pt) Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos
AR011521A1 (es) Un derivado de la prolil-3-(2-naftil) alanil-n-bencil-n-metilamida, un procedimiento para su preparacion y una composicion farmaceutica que lo comprende
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
AR019496A1 (es) Azalidas de 13 miembros, composiciones farmaceuticas, uso en la preparacion de medicamentos y preparacion de los mismos
BR0215277A (pt) Dicetopiperazinas substituìdas como antagonistas da oxitocina
ES2114721T3 (es) Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos.
MY113863A (en) Method for preparing n, n' - disubstituted cyclic ureas
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
ES2114722T3 (es) Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos.
ES2080726T3 (es) Compuestos aromaticos o heteroaromaticos nitrosustituidos para su utilizacion en el tratamiento del cancer.
EA200100969A1 (ru) Новые соединения циклобутендиона, способ их получения и содержащие их фармацевтические композиции
CO5590934A2 (es) Procedimiento de preparacion de derivados de equinocandina
AR027578A1 (es) Derivados de indano
FR2393577A1 (fr) Medicament a base d'acide b-(p-halogenophenyl)-g-aminobutyrique destine au traitement de la nevrose d'angoisse
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
ES2043070T3 (es) Procedimiento para la preparacion de derivados de la benzotiazolamina-2.
BR0010225A (pt) Composto de amida, processo para prepará-lo, composição farmacêutica compreendendo dito composto, método de tratamento e uso
ES8506651A1 (es) Un metodo de preparar fenilalquil(piperazinil u homopiperazinil)propil-(ureas y tioureas) sustituidas

Legal Events

Date Code Title Description
FG Grant, registration